Posted by Michael Wonder on 02 Jan 2023
With FDA accelerated approval of Alzheimer’s drug lecanemab likely 6 January, discussion turns to price and reimbursement
2 January 2023 - Lecanemab’s PDUFA date for its potential accelerated approval is 6 January.
The product could launch after its approval by the FDA. And so now the discussion turns to what price it will be launched at, as well as whether it will eventually be reimbursed by Medicare, the predominant payer for a product such as lecanemab.
